Intimation for appointment of an internal, secretarial & Cost auditors is attached
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.3 pts less than Nifty Microcap 250 and 0.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Mercury Laboratories reported FY25 revenue of ₹7,510.12 lakhs (vs ₹7,555.90 lakhs last year, a marginal ~0.6% decline), while net profit after tax fell sharply to ₹314.49 lakhs from ₹565.42 lakhs (down ~44%). Q4 FY25 revenue grew ~19% year-on-year to ₹2,065.91 lakhs, but Q4 PAT declined to ₹111.04 lakhs from ₹191.03 lakhs. The board recommended a final dividend of ₹3.50 per share (35%) subject to shareholder approval. Statutory auditors (Naresh & Co.) issued an unmodified opinion. Key board changes include appointment of Mr. Sanjay Patel as Independent Director & Chairman, re-appointment of Mr. Rajendra Shah as MD for 3 years from April 2026, and retirement of Mr. Bharat Mehta. The board also appointed Secretarial, Internal, and Cost Auditors for FY25-26.
Despite flat top-line, a sharp ~44% drop in annual profits signals significant margin pressure and rising costs (employee expenses up ~16%). The 35% dividend provides some return to shareholders, but weakening profitability and a 51% drop in operating cash flow may weigh on near-term sentiment.